Skip to content

Drinking alcohol on a GLP-1: what labels and research say

Updated Sep 30, 2026. Numbers in brackets link to the source each fact comes from.

None of the FDA labels for Wegovy, Zepbound, Foundayo, Ozempic or Mounjaro says anything about drinking alcohol. We searched each one on DailyMed: the word appears only for alcohol swabs and inactive ingredients. What the labels do contain are two warnings, pancreatitis and low blood sugar, where drinking is relevant according to federal health agencies.

Pancreatitis

Every one of these labels warns about acute pancreatitis. The Wegovy label says to watch for persistent or severe belly pain, sometimes spreading to the back, with or without nausea or vomiting, and to stop the drug if pancreatitis is suspected [1]. The Zepbound label notes that fatal and non-fatal cases have been seen with GLP-1 medicines [2].

Alcohol is a separate cause. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) says alcohol misuse over time can lead to pancreatitis [3]. The labels do not say whether drinking changes the pancreatitis risk on a GLP-1. If you drink heavily or have had pancreatitis before, tell your prescriber before starting.

Low blood sugar

The labels tie a higher risk of low blood sugar to combining these medicines with certain diabetes drugs:

  • The Wegovy label says people with diabetes who also take insulin or an insulin secretagogue, such as a sulfonylurea, may have a higher risk of low blood sugar, including severe episodes [4].
  • In a Zepbound trial in people with type 2 diabetes, low blood sugar was reported in 10.3% of those also taking a sulfonylurea, against 2.1% of those who were not [5].

Alcohol adds to that. In its guide to low blood glucose for people with diabetes, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) lists drinking too much without enough food as a cause, and says alcohol can hide the first symptoms of a low [6]. It advises eating something when you drink [7]. This matters most if you take insulin or a sulfonylurea along with your GLP-1.

Can a GLP-1 reduce drinking?

Researchers are testing this, but no GLP-1 label lists alcohol use disorder among its approved uses.

  • Semaglutide trial, 2025. A small phase 2 trial randomized 48 adults with alcohol use disorder who were not seeking treatment, for 9 weeks [8]. Doses were low, rising from 0.25 mg to 1.0 mg a week [9]. People on semaglutide drank less in a supervised lab drinking session [10]. In daily life, it did not change how many days they drank or their average drinks per day, but it did cut drinks on the days they drank and weekly craving [11]. The authors call this initial evidence that justifies larger trials [12].
  • Exenatide trial, 2022. An older GLP-1 medicine was tested in 127 people with alcohol use disorder and did not reduce heavy drinking days overall [13]. An exploratory look found fewer heavy drinking days in participants with a BMI over 30 [14].
  • Animal research. NIAAA scientists found semaglutide cut alcohol intake and binge-like drinking in rodents [15], and the institute describes GLP-1 medicines as showing potential for treating alcohol use disorder [16].

So far this is early evidence, not a treatment. The human trials were small and short [8] [13], and they cannot yet say how large an effect is or who it helps.

What users say has been studied once in a published paper, though not in a controlled trial. Researchers recruited 153 current drinkers with obesity for a remote study; some were taking semaglutide or tirzepatide for at least 30 days, and the rest took no medicine for diabetes or weight loss [18]. Those on either drug reported drinking less, fewer drinks per occasion, lower odds of binge drinking and weaker stimulating and sedative effects from alcohol, both compared with before they started and compared with the other group [19]. The same paper sorted Reddit posts about these drugs: of 1,580 posts about alcohol, 71% described less craving, less desire to drink or other negative effects of drinking [20]. These are self-reports, so they cannot show that the drug caused the change.

Practical points

  • Tell your prescriber how much you drink. It matters for pancreatitis risk and, if you have diabetes, for low blood sugar.
  • If you take insulin or a sulfonylurea, eat when you drink and know the signs of a low [6] [7].
  • The Wegovy Medication Guide says to stop the medicine and call your provider right away for severe stomach pain that will not go away, which may reach your back [17].
  • If you want help cutting back, a GLP-1 is not an approved option for that. Ask your doctor about treatments for alcohol use disorder.

Sources

  1. After initiation of WEGOVY, observe patients carefully for signs and symptoms of acute pancreatitis, which may include persistent or severe abdominal pain (sometimes radiating to the back), and which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue WEGOVY and initiate appropriate management. dailymed.nlm.nih.gov, read Sep 27, 2026.
  2. Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, or ZEPBOUND dailymed.nlm.nih.gov, read Sep 27, 2026.
  3. Alcohol misuse over time can lead to pancreatitis, which can impair the production of digestive enzymes and can affect hormones that regulate blood sugar level. niaaa.nih.gov, read Sep 27, 2026.
  4. Patients with diabetes mellitus taking WEGOVY in combination with insulin or an insulin secretagogue may have an increased risk of hypoglycemia, including severe hypoglycemia. dailymed.nlm.nih.gov, read Sep 27, 2026.
  5. patients taking ZEPBOUND in combination with an insulin secretagogue (e.g., sulfonylurea) had increased risk of hypoglycemia (10.3%) compared to ZEPBOUND-treated patients not taking a sulfonylurea (2.1%). dailymed.nlm.nih.gov, read Sep 27, 2026.
  6. Drinking too much alcohol without enough food. Alcohol makes it harder for your body to keep your blood glucose level steady, especially if you haven’t eaten in a while. Alcohol can also keep you from feeling the first symptoms of low blood glucose, which can lead to severe symptoms. niddk.nih.gov, read Sep 27, 2026.
  7. Also, if you drink alcoholic beverages, it’s safer to eat some food at the same time. niddk.nih.gov, read Sep 27, 2026.
  8. This was a phase 2, double-blind, randomized, parallel-arm trial involving 9 weeks of outpatient treatment. Enrollment occurred at an academic medical center in the US from September 2022 to February 2024. Of 504 potential participants assessed, 48 non-treatment-seeking participants with AUD were randomized. pubmed.ncbi.nlm.nih.gov, read Sep 27, 2026.
  9. Participants received semaglutide (0.25 mg/week for 4 weeks, 0.5 mg/week for 4 weeks, and 1.0 mg for 1 week) or placebo at weekly clinic visits. pubmed.ncbi.nlm.nih.gov, read Sep 27, 2026.
  10. Low-dose semaglutide reduced the amount of alcohol consumed during a posttreatment laboratory self-administration task pubmed.ncbi.nlm.nih.gov, read Sep 27, 2026.
  11. Semaglutide treatment did not affect average drinks per calendar day or number of drinking days, but significantly reduced drinks per drinking day (β, -0.41; 95% CI, -0.73 to -0.09; P = .04) and weekly alcohol craving (β, -0.39; 95% CI, -0.73 to -0.06; P = .01) pubmed.ncbi.nlm.nih.gov, read Sep 27, 2026.
  12. These findings provide initial prospective evidence that low-dose semaglutide can reduce craving and some drinking outcomes, justifying larger clinical trials to evaluate GLP-1RAs for alcohol use disorder. pubmed.ncbi.nlm.nih.gov, read Sep 27, 2026.
  13. A total of 127 patients were enrolled. Our data revealed that although exenatide did not significantly reduce the number of heavy drinking days compared with placebo pubmed.ncbi.nlm.nih.gov, read Sep 27, 2026.
  14. Exploratory analyses revealed that exenatide significantly reduced heavy drinking days and total alcohol intake in a subgroup of obese patients (BMI > 30 kg/m2). pubmed.ncbi.nlm.nih.gov, read Sep 27, 2026.
  15. found that semaglutide reduces alcohol consumption and binge-like drinking in a rodent model of alcohol misuse. niaaa.nih.gov, read Sep 27, 2026.
  16. GLP-1 receptor agonists show potential for treating people with alcohol use disorder (AUD) niaaa.nih.gov, read Sep 27, 2026.
  17. Stop using WEGOVY and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back. dailymed.nlm.nih.gov, read Sep 27, 2026.
  18. Secondly, we recruited participants (n = 153; current alcohol drinkers; BMI ≥ 30) who self-reported either taking Semaglutide (GLP-1 agonist), Tirzepatide (the GLP-1/GIP combination) for ≥ 30 days or, as a control group; no medication to manage diabetes or weight loss for a within and between subject remote study. pubmed.ncbi.nlm.nih.gov, read Sep 28, 2026.
  19. In the remote study, we observe a significantly lower self-reported intake of alcohol, drinks per drinking episode, binge drinking odds, Alcohol Use Disorders Identification Test (AUDIT) scores, and stimulating, and sedative effects in the Semaglutide or Tirzepatide group when compared to prior to starting medication timepoint (within-subjects) and the control group (between-subjects). pubmed.ncbi.nlm.nih.gov, read Sep 28, 2026.
  20. Among the alcohol-related posts (n = 1580), 71% were identified as craving reduction, decreased desire to drink, and other negative effects. pubmed.ncbi.nlm.nih.gov, read Sep 28, 2026.

This page reports what official sources say; it is not medical advice. Medical disclaimer.